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One sentence summary: 43 
The PGP3 ELISA has potential for sero-epidemiological studies of current and/or past 44 
chlamydial infection of women in a variety of settings, including high prevalence.   45 
 46 
ABSTRACT  47 
Serological assays can be used to investigate the population burden of infection and 48 
potentially sequelae from Chlamydia. We investigated the PGP3 ELISA as a sero-49 
epidemiological tool for infection or sub-fertility in Australian and Samoan women. 50 
The PGP3 ELISA absorbance levels were compared between groups of women with 51 
infertility, fertile, and current chlamydial infections. In the Australian groups, women 52 
with chlamydial tubal factor infertility had significantly higher absorbance levels in the 53 
PGP3 ELISA compared to fertile women (p<0.0001), but not when compared to 54 
women with current chlamydial infection (p=0.44). In the Samoan study, where the 55 
prevalence of chlamydial infections  is much higher there were significant differences 56 
in the PGP3 ELISA absorbance levels between chlamydial sub-fertile women and 57 
fertile women (p=0.003). There was no difference between chlamydial sub-fertile 58 
women and women with a current infection (p=0.829). The results support that the 59 
PGP3 assay is effective for sero-epidemiological analysis of burden of infection, but 60 
not for evaluation of chlamydial pathological sequelae such as infertility. 61 
 62 
  63 
 64 
INTRODUCTION  65 
 66 
Chlamydia trachomatis is the most common bacterial sexually transmitted 67 
infection worldwide. Infections can result in serious sequelae such as pelvic 68 
inflammatory disease, tubal factor infertility (TFI), and ectopic pregnancy (reviewed 69 
(Menon et al., 2015)). Estimating the population attributable risk of these sequelae is 70 
difficult as they have multiple aetiologies and are often not diagnosed until sometime 71 
after infection (Menon et al., 2015). Serological assays have the potential to be used in 72 
population studies to estimate the burden of sequelae attributable to chlamydia, and to 73 
evaluate and monitor health interventions. 74 
Ades et al., 2017 evaluated whole organism immunofluorescence titres (WIF)  75 
across a 10 year period, for women undergoing care for tubal factor infertility (Ades et 76 
al., 2017). Titres were analysed using a finite mixture models approach to estimate the 77 
population excess fraction of chlamydial TFI (case-control study of TFI compared with 78 
female infertility from other causes) to be 28% (95% credible interval [CrI]: 5–95%) 79 
and maximum of 46.8% (95% CrI: 23.3–64.1%) (Ades et al., 2017). The population 80 
burden beyond the infertility setting remains less well characterised, and relatively few 81 
sero-epidemiological studies have included fertile women as controls (Menon et al., 82 
2016).  83 
Numerous studies have shown that chlamydial sero-positivity, in infertile 84 
women has been significantly associated with laparoscopically-diagnosed TFI (Gijsen 85 
et al., 2002, Akande et al., 2003, Land et al., 2010). However, the sensitivity and 86 
specificity of the assays used vary considerably. Recent studies in the UK have 87 
demonstrated that the Pgp3 ELISA (enzyme linked immunosorbent assay) (Wills et al., 88 
2009, Horner et al., 2016) could be used for such monitoring and evaluating (Horner et 89 
al., 2013, Horner et al., 2016, Woodhall et al., 2017). Here, we explored the Pgp3 90 
ELISA as a surveillance assay in women from Australia and Samoa who have 91 
infertility/sub-fertility, fertility, or current infection (Huston et al., 2010, Walsh et al., 92 
2015, Menon et al., 2016, Menon et al., 2016).   93 
 94 
MATERIALS AND METHODS  95 
 96 
Study design and participant groups 97 
 The study aimed to evaluate if the PGP3 ELISA could be used for estimating 98 
the burdens of chlamydial infertility and/or infection in women from Australia and 99 
Samoa. We tested absorbance levels in the PGP3 ELISA using a 1/100 serum dilution, 100 
from previously described samples (Huston et al., 2010, Walsh et al., 2015, Menon et 101 
al., 2016, Menon et al., 2016). Participants from Australia (n=302) were categorised 102 
into four groups. Group 1 was infertile women with greater than a year of trying to 103 
conceive, who all had laparoscopic investigations for tubal occlusion (Menon et al., 104 
2016). Past chlamydial infection measured by MIF was used to define chlamydial TFI. 105 
Group 2 were fertile women attending antenatal care, who had never had assisted 106 
reproductive technologies and whose current pregnancy took less than one year to 107 
conceive (Menon et al., 2016). Group 3 were women attending University General 108 
Practice or Sexual Health Clinics with a NAAT confirmed chlamydial infection 109 
(Huston et al., 2010, Menon et al., 2016) (serum was typically collected when 110 
participants returned for treatment, within 1 week). Group 4 was a separate group of 111 
infertile women, in this group chlamydial sero-positivity (MIF) and tubal factor 112 
infertility diagnosis were used to define chlamydial TFI  (Menon et al., 2016).  Group 113 
5 (n=239) were from a previously described study in Samoa (high chlamydia 114 
prevalence) where urine for PCR and blood for serum was collected at the same time 115 
(Walsh et al., 2015, Menon et al., 2016). The serological results from Samoan women 116 
were analysed using two groupings (Table 1). First, based on epidemiological data, and 117 
previous serological results (MIF), they were categorised into chlamydial sub-fertile or 118 
fertile. The second analysis was by grouping the participants from Samoa into women 119 
who had a infection confirmed by NAAT compared to currently NAAT negative 120 
women. 121 
 122 
ELISA Protocol and analysis 123 
PGP3 ELISA was conducted as previously described (Wills et al., 2009), with 124 
the exception that the blocking agent was skim milk powder (0.5%). Samples were re-125 
tested or excluded when the standard error deviated by more than 5% within the 126 
replicates (mean of replicates were analysed).  All analysis was conducted in IBM SPSS 127 
V 25. 128 
 129 
Ethics statement 130 
The study was reviewed by Human Research Ethics Committees and each participant 131 
provided informed written consent. Human Research Committee Ethical Approvals 132 
include: Monash Private Surgical Human Research Ethics Committee (HREC) 133 
(12099); UC Health HREC (1221); Prince Charles Hospital HREC (EC2809); Ipswich 134 
and West Moreton Health Services District HREC (10-09), Gold Coast Hospital 135 
District HREC (200893); Cairns Sexual Health HREC (09/QCH/4–554); Queensland 136 
University of Technology HREC (080000268); and University of Technology Sydney 137 
HREC (2015000699), and initial ethical approval was from National University of 138 
Samoa, Samoa National Health Service Board approval for the use of the Laboratory 139 
and staff, and the Samoa Ministry of Women approved the village based survey, and 140 
the Samoan Ministry of Health.  141 
 142 
RESULTS  143 
 144 
 The PGP3 ELISA absorbance level was significantly higher when chlamydia infertile 145 
(or sub-fertile) women were compared with women who were infertile (or sub-fertile) 146 
for other reasons (n=11, n=86 respectively, Group 1: p<0.0001) in only one of two 147 
groups in Australia (Table 1). Women who were categorized as chlamydia sub-fertile 148 
from Samoa had a significantly higher absorbance than the rest of that population (n=29 149 
A=2.9, n= 134 A= 2.12 respectively; p=0.016) (Table 1). In both Australian and 150 
Samoan women, the PGP3 ELISA absorbance levels in women with chlamydial sero-151 
positivity by MIF and who had TFI or sub-fertility were not significantly different from 152 
women with current infections (Table 1),. However, the PGP3 ELISA absorbance level 153 
was significantly higher in women in Australia with a confirmed infection (Group 3, 154 
n=79) compared to all groups except chlamydial tubal factor infertility (Table 1). 155 
Similarly in the participants recruited in Samoa, women with a current  infection had 156 
high PGP3 ELISA absorbance levels, that were significantly different from women who 157 
were currently infected (mean Abs 3.16, p<0.0001, n=86, n=153). Furthermore, this 158 
was also higher than infected participants in Australia (mean Abs: 2.10, p<0.0001) 159 
likely due to the higher prevalence of Chlamydia and lower access to testing and 160 




Whilst diagnosis of current chlamydial infections is effective using NAATs, 165 
detection of and population level understanding of the burden of infection and disease 166 
sequelae is not possible using NAATs. Here, we present an evaluation of the PGP3 167 
ELISA in the Australian and Samoan context comparing chlamydial infertile, fertile, 168 
and current infection groups. We report that the PGP3 ELISA absorbance levels were 169 
significantly different in chlamydial infertile or sub-fertile women compared with 170 
fertile women in Australia, but only in one fertility clinic setting and not in another. 171 
However, the numbers were small in one group (n=5). Additionally, as we used MIF to 172 
define Chlamydia infertility, which is reported to have variability in the sensitivity and 173 
specificity depending on the reagent preparation and  which have haveChlamydia 174 
pneumoniae cross-reactivity could mean some of these participants are mis-assigned 175 
(Clad et al., 1994, Akande et al., 2003). Previously, such cross-reactivity has been 176 
resolved using multiple assays, such as PGP3, but given we are assessing PGP3 in this 177 
context we can only interpret this result with caution (Ades et al., 2017). There was 178 
also significant difference when comparing chlamydial sub-fertile women in Samoa 179 
with fertile or sub-fertile for other reasons (p=0.016). However, in both settings 180 
chlamydia infertile or sub-fertile women had PGP3 ELISA absorbance levels that were 181 
not significantly different from women with current infections. The groups of women 182 
with current infections in both Samoa and Australia had significantly higher absorbance 183 
levels than all other groups (apart from chlamydial infertile) supporting that infectious 184 
burden can be successfully evaluated using this assay in population studies.  185 
One limitation of this study is that we used a single antibody dilution and 186 
conducted all measures on absorbance levels, rather than antibody titres. This method 187 
is likely to underestimate the differences in serum antibody levels because antibody 188 
responses are not linear. It is important that more work is conducted in high prevalence 189 
setting such as Samoa, as our study is too small to draw conclusions, although the 190 
findings support implementation of the PGP3 ELISA as a sero-epidemiological tool. 191 
AIn neither the higher or lower prevalence groups of women tested here, did we see a 192 
consistent significant difference in the absorbance between women with a current 193 
infection and chlamydial infertility or sub-fertility, and in future serological studies 194 
using this ELISA it should be considered that positive result could indicate current or 195 
recent infection. However, there are several studies that report specific, but not sensitive 196 
antigens for chlamydial infertility or pathology (e.g. CT117/CT223  for Ct and cancer; 197 
HtrA and OmcB for infertility; HtrA and TroA for pathology; and CT443 and CT381 198 
for infertility; and 11 different peptides for infertility), and it could be that a double or 199 
multiple antigen approach including PGP3 with these antigens could be implemented 200 
to measure population burdens of chlamydial infertility (Menon et al., 2016) (Stansfield 201 
et al., 2013) (Rodgers et al., 2011, Hokynar et al., 2017, Hufnagel et al., 2018, Rahman 202 
et al., 2018). Overall, the data presented here add to the evidence that the PGP3 ELISA 203 
could be an effective sero-epidemiological tool to evaluate the burden of chlamydial 204 
infection in women in a population. 205 
 206 
CONCLUSIONS 207 
The data presented here means we now have a global dataset (in conjunction 208 
with the recent UK studies (Horner et al., 2013, Woodhall et al., 2017)) supporting that 209 
the PGP3 ELISA has potential for sero-epidemiological studies of current and/or past 210 
chlamydial infection of women. We propose the assay could be used for longitudinal 211 
sero-epidemiological monitoring of public health intervention programs to control and 212 
reduce Chlamydia.  213 
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